2012, Number 1
<< Back Next >>
Ann Hepatol 2012; 11 (1)
Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors?
Aydin S
Language: English
References: 14
Page: 145-146
PDF size: 51.80 Kb.
Text Extraction
To the Editor
I have read the article about the changes in ghrelin
and obestatin levels authored by Dr. Gutierrez-
Grobe,
et al. and published in Annals of
Hepatology with great interest. Ghrelin and obestatin
are peptide hormones which are easily broken
down by proteases
REFERENCES
Gutierrez-Grobe Y, Villalobos-Blasquez I, Sánchez-Lara K, Villa AR, Ponciano-Rodríguez G, Ramos MH, Chavez-Tapia NC, Uribe M, Méndez-Sánchez N. High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol 2010; 9: 52-7.
Hosoda H, Doi K, Nagaya N, Okumura H, Nakagawa E, Enomoto M, Ono F, Kangawa K. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem 2004; 50: 1077-108.
Blatnik M, Soderstrom CI. A practical guide for the stabilization of acylghrelin in human blood collections. Clin Endocrinol 2011; 74: 325-31.
Available from: http://www.phoenixpeptide.com.
Available from: http://www.bioquote.com.
Aydin S, Sahin I, Demirel U, Aksoy A. To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease? Metabolism 2011; 60: 1.
Aydin S. Discovery of ghrelin hormone: research and clinical applications. Turk J Biochem 2007; 32: 76-89.
Rawlings ND, Barrett AJ, Bateman A. MEROPS: the peptidase
database. Nucleic Acids Res 2010; 38: 227-33.
Gutierrez-Grobe Y, et al. High ghrelin and obestatin levels and low risk of developing fatty liver. Annals of Hepatology 2010; 9: 52-7.
Blatnik M, Soderstrom CI. A practical guide for the stabilization of acylghrelin in human blood collections. Clinical endocrinol 2011; 74: 325-31.
Chavez-Tapia NC, et al. Smoking is not associated with nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5196-200.
Mendez-Sanchez N, et al. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11: 1737-41.
French BA, et al. The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation. Experimental and molecular pathology 2011; 90: 252-6.